Şunu aradınız:: desloratadinom (Slovence - İngilizce)

neželeni učinki, opaženi pri zdravljenju z desloratadinom
adverse reactions seen with desloratadine

Študije z desloratadinom in loratadinom so pokazale, da nista kancerogena.
the lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine.

odsotnost kancerogenih učinkov so pokazali v raziskavah z desloratadinom in loratadinom.
the lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine.

odsotnost kancerogenih učinkov je bila dokazana v študijah z desloratadinom in loratadinom.
the lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine.

v obeh študijah so zdravilo aerinaze primerjali s samim desloratadinom in s samim psevdoefedrinom.
in both studies, aerinaze was compared with desloratadine alone and with pseudoephedrine alone.

učinkovitosti tablet z desloratadinom niso jasno dokazali v preskušanjih pri mladostnikih, starih od 12 do 17 let.
the efficacy of desloratadine tablets has not been clearly demonstrated in trials with adolescent patients 12 through 17 years of age.

po zmanjšanju kongestije sluznice zgornjih dihal lahko zdravljenje nadaljujete tudi samo z desloratadinom, če je potrebno.
after improvement of the congestive condition of the mucosae of the upper airway, treatment may be maintained with desloratadine alone, if necessary.

zdravljenje z desloratadinom je tudi bistveno zmanjšalo motnje spanja in delovanje čez dan, kot so ugotovili z uporabo štiritočkovne lestvice za oceno teh spremenljivk.
treatment with desloratadine also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables.

predklinične raziskave z desloratadinom in loratadinom so pokazale, da ni kakovostnih ali količinskih razlik med profiloma toksičnosti desloratadina in loratadina pri primerljivi ravni izpostavljenosti desloratadinu.
non-clinical studies conducted with desloratadine and loratadine demonstrated that there are no qualitative or quantitative differences in the toxicity profile of desloratadine and loratadine at comparable levels of exposure to desloratadine.

v kliničnih preskušanjih z desloratadinom, v katerih so bolniki sočasno jemali tudi eritromicin ali ketokonazol, pa niso opazili nikakršnih klinično pomembnih interakcij ali sprememb plazemske koncentracije desloratadina.
however, no clinically relevant interactions or changes in desloratadine plasma concentrations were observed in clinical trials with desloratadine in which erythromycin or ketoconazole were co-administered.

odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z desloratadinom, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
a decision must be made whether to discontinue breast-feeding or to discontinue/abstain from desloratadine therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

ta se je pojavil pri 5, 9% bolnikov, zdravljenih z desloratadinom, in pri 6, 9% bolnikov, zdravljenih s placebom.
other undesirable effects reported very rarely during the post-marketing period are listed in the following table.

pri 55 % bolnikov, zdravljenih z desloratadinom, so ugotavljali več kot 50 % izboljšanje srbenja, v primerjavi z 19 % bolnikov, zdravljenih s placebom.
an improvement in pruritus of more than 50 % was observed in 55 % of patients treated with desloratadine compared with 19 % of patients treated with placebo.